aTyr Pharma, Inc. Forecast, price target & analysts
aTyr Pharma, Inc. Target price 2025 - Analyst rating & recommendation
aTyr Pharma, Inc. Classifications & Recommendation:
aTyr Pharma, Inc. Price Target
| Target Price | $1.02 |
| Price | $0.77 |
| Potential |
32.33%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target aTyr Pharma, Inc. 2026 .
The average aTyr Pharma, Inc. target price is $1.02.
This is
32.33%
register free of charge
$21.00
2,624.44%
register free of charge
$1.01
31.03%
register free of charge
|
|
| A rating was issued by 17 analysts: 9 Analysts recommend aTyr Pharma, Inc. to buy, 8 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the aTyr Pharma, Inc. stock has an average upside potential 2026 of
32.33%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.24 | 1.22 |
| 31.43% | 410.00% | |
| EBITDA Margin | -28,004.17% | -5,945.83% |
| 80.41% | 78.77% | |
| Net Margin | -26,675.00% | -6,001.89% |
| 85.28% | 77.50% |
13 Analysts have issued a sales forecast aTyr Pharma, Inc. 2025 . The average aTyr Pharma, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an aTyr Pharma, Inc. EBITDA forecast 2025. The average aTyr Pharma, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 aTyr Pharma, Inc. Analysts have issued a net profit forecast 2025. The average aTyr Pharma, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.86 | -0.75 |
| 8.51% | 12.79% | |
| P/E | negative | |
| EV/Sales | negative |
13 Analysts have issued a aTyr Pharma, Inc. forecast for earnings per share. The average aTyr Pharma, Inc. EPS is
This results in the following potential growth metrics and future valuations:
aTyr Pharma, Inc....
Current aTyr Pharma, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 15 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Aug 22 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Jun 20 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 04 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 16 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Sep 16 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 15 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Aug 22 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Jun 20 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 04 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
